Search clinical trials for: Isatuximab Carfilzomib Lenalidomide Dexamethasone

Total 487 results

Hackensack Meridian Health

Terminated

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Multiple Myeloma

United States
Takeda

Completed

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States, Canada
Takeda

Withdrawn

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma (US MM-7)

Multiple Myeloma
Millennium Pharmaceuticals, Inc.

Completed

A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
PETHEMA Foundation
Millennium Pharmaceuticals, Inc.; Celgene

Completed

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Multiple Myeloma

Spain
Hospital Universitari Vall d'Hebron Research Institute

Completed

Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09)

Chronic Lymphatic Leukemia

Spain
Larysa Sanchez
Janssen, LP

Recruiting

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Newly Diagnosed Multiple Myeloma

United States
Paul Richardson, MD
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts... and other collaborators

Active, not recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

Multiple Myeloma

United States
Nantes University Hospital

Completed

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) (IFM2013-06)

Newly Diagnosed Multiple Myeloma

France
Nantes University Hospital

Completed

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Amyloidosis

France
University of Miami
Amgen; Janssen Pharmaceuticals

Recruiting

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)

Multiple Myeloma

United States, Sweden
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Neoplasms | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease | Neoplasm, Plasma Cell

Greece
University Hospital, Toulouse

Recruiting

Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma (IFM2018-01)

Multiple Myeloma

France
Takeda

Active, not recruiting

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Multiple Myeloma

United States
Dana-Farber Cancer Institute
Takeda; Celgene

Active, not recruiting

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, France, Korea, Republic of, Canada, Belgium, New Zealand, Russian Federation
Emory University
Merck Sharp & Dohme LLC; Celgene Corporation

Completed

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Dana-Farber Cancer Institute
Novartis

Completed

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma (PanRVD)

Multiple Myeloma in Relapse

United States
University Hospital, Toulouse
Takeda; Celgene

Terminated

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma (IFM2014-03)

Multiple Myeloma

France
Weill Medical College of Cornell University
Pfizer; Celgene Corporation

Terminated

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma (PD + RD)

Multiple Myeloma

United States
Fondazione EMN Italy Onlus

Completed

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Multiple Myeloma

Italy
PETHEMA Foundation

Completed

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)

Primary Systemic Amyloidosis

Spain
King's College Hospital NHS Trust

Completed

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma (CRD)

Multiple Myeloma

United Kingdom
University of Alabama at Birmingham
Janssen Scientific Affairs, LLC

Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Multiple Myeloma

United States
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Fondazione EMN Italy Onlus

Active, not recruiting

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Multiple Myeloma

Italy
Janssen-Cilag International NV

Completed

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD (SEQUENTIAL)

Multiple Myeloma

France, United Kingdom, Spain, Poland, Serbia, Turkey, Greece, Germany, Hungary, Lithuania
Alliance Foundation Trials, LLC.
Takeda; Janssen Scientific Affairs, LLC; Celgene Corporation

Active, not recruiting

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Myeloma, Multiple

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, New Zealand
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Multiple Myeloma Research Consortium; Blood Cancer Research...

Completed

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States
PETHEMA Foundation
Celgene; Janssen-Cilag Ltd.; TFS Trial Form Support

Completed

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Multiple Myeloma

Spain
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Myeloma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
Merck Sharp & Dohme LLC

Completed

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)

Completed

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (ADCC)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Amgen

Terminated

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Withdrawn

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia, Germany, Japan, Spain, United States, Italy, Poland
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Multiple Myeloma

United States
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Denmark, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Argentina, Sweden, Canada, Spain, Germany, Netherlands, France, Brazil, Greece, Poland, Ireland, Hungary, Portugal, Australia, F... and more
University of Turin, Italy

Recruiting

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Multiple Myeloma

Italy
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Terminated

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Multiple Myeloma

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Multiple Myeloma

United States, France, Spain
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Amgen
Innovative Therapies For Children with Cancer Consortium; Therapeutic Advances...

Active, not recruiting

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)

Spain, United Kingdom, United States, Korea, Republic of, Czechia, France, Russian Federation, Saudi Arabia, Thailand, Canada, Italy, Singapore, Turkey, Taiwan, Portugal, Poland, Romania, Brazil, Australia, Greece, Argentina, Mexico, Austr... and more
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Juan Du

Recruiting

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Multiple Myeloma

China
University of Leeds
Celgene; Janssen, LP; Myeloma UK

Active, not recruiting

MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)

Multiple Myeloma

United Kingdom
Weill Medical College of Cornell University
Celgene Corporation

Terminated

BiRd vs. Rd as Initial Therapy in Multiple Myeloma (BiRd vs Rd)

Multiple Myeloma

United States

3

Subscribe